Sensus Healthcare Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
SRTS$3.30+3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| (in thousands) · 2024 · 2023 | ||||
| Cash flows from operating activities | ||||
| Net income (loss) | $2,274 | $(1,894) | ||
| Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities: | ||||
| Depreciation and amortization | 70 | 73 | ||
| Amortization of right-of-use asset | 48 | 48 | ||
| Provision for product warranties | 150 | 163 | ||
| Stock-based compensation | 91 | 143 | ||
| Deferred income taxes | 827 | (802) | ||
| Decrease (increase) in: | ||||
| Accounts receivable | (8,980) | 4,566 | ||
| Inventories | (2,865) | (2,855) | ||
| Prepaid inventory | (685) | (3,370) | ||
| Other current assets | (281) | (315) | ||
| Other noncurrent assets | 116 | 1 | ||
| Increase (decrease) in: | ||||
| Accounts payable and accrued expenses | 910 | (593) | ||
| Operating lease liability | (39) | (46) | ||
| Income tax payable | - | (890) | ||
| Deferred revenue | 271 | (35) | ||
| Product warranties | (94) | (191) | ||
| Total adjustments | (10,461) | (4,103) | ||
| Net cash used in operating activities | (8,187) | (5,997) | ||
| Cash flows from investing activities | ||||
| Acquisition of property and equipment | (233) | (189) | ||
| Net cash used in investing activities | (233) | (189) | ||
| Cash flows from financing activities | ||||
| Withholding taxes on stock-based compensation | - | (40) | ||
| Exercise of stock options | - | 46 | ||
| Net cash provided by financing activities | - | 6 | ||
| Net decrease in cash and cash equivalents | (8,420) | (6,180) | ||
| Cash and cash equivalents – beginning of period | 23,148 | 25,520 | ||
| Cash and cash equivalents – end of period | $14,728 | $19,340 | ||
| Supplemental disclosure of cash flow information: | ||||
| Interest paid | $ | - | $ | - |
| Income tax paid | $ | - | $1,200 | |
| Supplemental schedule of noncash investing and financing transactions: | ||||
| Transfer of inventory to property and equipment | $6 | $14 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.